(CercleFinance.com) – Roche announced Thursday that Health Canada has authorized the marketing of Polivy for the treatment of adult patients with untreated large B-cell lymphoma.
Large B-cell lymphomas, a form of blood cancer, include a wide spectrum of tumors that affect lymphocytes in the lymphatic system, which produce antibodies to fight bacteria, viruses and other foreign substances such as fungi.
Among non-Hodgkin’s lymphomas, large B-cell lymphoma remains the most common, with an estimated 11,400 new patients diagnosed in Canada this year.
Polivy, an antibody-drug conjugate, releases an antimitotic agent into B cells resulting in malignant B cell death.
After more than 20 years with no real breakthrough in the first-line treatment of the disease, Polivy reduces the risk of death or disease progression/recurrence by 27%, compared to the current standard treatment, according to phase data. III collected over 28 months.
Copyright (c) 2022 CercleFinance.com. All rights reserved.